Form 4: MIRA Director Acquires 22,378 Shares as Acquisition Compensation

MIRA Pharmaceuticals Director Denil Nanji Shekhat acquired 22,378 shares of common stock as compensation for the acquisition of SKNY Pharmaceuticals, Inc.

Summary

• Denil Nanji Shekhat, a Director and 10% Owner of MIRA Pharmaceuticals, Inc. (MIRA), acquired 22,378 shares of common stock.
• The transaction occurred on October 1, 2025, with a deemed execution date of the same day.
• These shares were issued as compensation for MIRA's acquisition of SKNY Pharmaceuticals, Inc.
• The shares were acquired at a price of $1.35 per share.
• Following this transaction, Denil Nanji Shekhat beneficially owns 22,378 shares directly.

Sentiment

Score: 6

Explanation: The filing reports an insider acquisition of shares as compensation for a corporate acquisition. While indicating strategic activity and potential management alignment, it does not provide performance metrics, leading to a neutral to slightly positive sentiment.

Positives

• The issuance of shares as compensation for an acquisition suggests the completion or progress of a strategic corporate action (acquisition of SKNY Pharmaceuticals, Inc.).
• A director acquiring shares, even as compensation, can be seen as an alignment of interests with shareholders.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction related to an acquisition, which is a common strategic move in the pharmaceutical industry for expanding pipelines or market share. Without further details on SKNY Pharmaceuticals, Inc. or the terms of the acquisition, a broader industry context cannot be fully assessed from this filing alone.

Related Party Transactions

• The issuance of 22,378 restricted shares of common stock to Denil Nanji Shekhat, a Director and 10% Owner, as compensation for the acquisition of SKNY Pharmaceuticals, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director may signal confidence in the company's future, potentially aligning management interests with shareholder value. The underlying acquisition of SKNY Pharmaceuticals, Inc. could impact future company performance and thus shareholder value.

Key Dates

Keywords

MIRA Pharmaceuticals, MIRA, Denil Nanji Shekhat, Form 4, Insider Transaction, Beneficial Ownership, Common Stock, Director, SKNY Pharmaceuticals, Acquisition Compensation